China-based Lynk Pharmaceuticals (Hangzhou) Co., Ltd announced first patient dosing in a Phase II clinical study assessing the efficacy and safety of its Category 1 innovative drug candidate LNK01003 in active ulcerative colitis (UC).
Ulcerative Colitis and LNK01003
Ulcerative colitis is one of the two main forms of inflammatory bowel disease (IBD), causing inflammation and ulceration of the inner lining of the rectum and colon. LNK01003 is a targeted kinase inhibitor under development to treat IBD, viewed as potentially more efficacious and safer than existing therapies, according to the announcement. A pre-clinical study showed that the drug allowed for low systemic exposure and high intestinal exposure, which is expected to help avoid the toxicity caused by systemic suppression of immunity.
Company Background
Lynk was founded by former drug research and development experts and executives from Pfizer, Merck, and Johnson & Johnson.-Fineline Info & Tech
